The American Journal of Medicine
Volume 122, Issue 10, Supplement , Pages S22-S32 , October 2009

Treatment of Neuropathic Pain: An Overview of Recent Guidelines

  • Alec B. O'Connor, MD, MPH

      Affiliations

    • Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    • Corresponding Author InformationRequests for reprints should be addressed to Alec B. O'Connor, MD, MPH, Department of Medicine, University of Rochester School of Medicine and Dentistry, Box MED/HMD, 601 Elmwood Avenue, Rochester, New York 14642
    • ,
  • Robert H. Dworkin, PhD

      Affiliations

    • Departments of Anesthesiology and Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA

References 

  1. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical research purposes. Neurology. 2008;70:1630–1635
  2. Oster G, Harding G, Dukes E, Edelsberg A, Cleary PG. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain. 2005;6:356–363
  3. Gore M, Brandenburg NA, Hoffman DL, Tai KS, Stacey B. Burden of illness in painful diabetic peripheral neuropathy: the patients' perspectives. J Pain. 2006;7:892–900
  4. McDermott AM, Toelle TR, Rowbotham DJ, Schaefer CP, Dukes EM. The burden of neuropathic pain: results of a cross-sectional survey. Eur J Pain. 2006;10:127–135
  5. Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology. 2007;68:1178–1182
  6. O'Connor AB. Neuropathic pain: a review of the quality of life impact, costs, and cost-effectiveness of therapy. Pharmacoeconomics. 2009;27:95–112
  7. Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain. 2004;5:143–149
  8. Dworkin RH, White R, O'Connor AB, Baser O, Hawkins K. Healthcare costs of acute and chronic pain associated with a diagnosis of herpes zoster. J Am Geriatr Soc. 2007;55:1168–1175
  9. Lachaine J, Gordon A, Choinière M, Collet JP, Dion D, Tarride JE. Painful neuropathic disorders: an analysis of the Régie de l'Assurance Maladie du Québec database. Pain Res Manag. 2007;12:31–37
  10. Dworkin RH, White R, O'Connor AB, Hawkins K. Healthcare expenditure burden of persisting herpes zoster pain. Pain Med. 2008;9:348–353
  11. Torrance N, Smith BH, Watson MC, Bennett MI. Medication and treatment use in primary care patients with chronic pain of predominantly neuropathic origin. Fam Pract. 2007;24:481–485
  12. Smith BH, Torrance N, Bennett MI, Lee AJ. Health and quality of life associated with chronic pain of predominantly neuropathic origin in the community. Clin J Pain. 2007;23:143–149
  13. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132:237–251
  14. Attal N, Cruccu G, Haanpää M, et al. EFNS Task Force EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. 2006;13:1153–1169
  15. Moulin DE, Clark AJ, Gilron I, et al. Canadian Pain Society Pharmacological management of chronic neuropathic pain—consensus statement and guidelines from the Canadian Pain Society. Pain Res Manage. 2007;12:13–21
  16. Oxford Centre for Evidence-based Medicine. Levels of evidence and grades of recommendation. http://www.cebm.net/index.aspx?o=1025Accessed March 24, 2009
  17. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 2005;352:1324–1334
  18. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain. 2005;118:289–305
  19. Roose SP, Laghrissi-Thode F, Kennedy JS, et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA. 1998;279:287–291
  20. Swenson JR, Doucette S, Fergusson D. Adverse cardiovascular events in antidepressant trials involving high-risk patients: a systematic review of randomized trials. Can J Psychiatry. 2006;51:923–929
  21. Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med. 2000;108:2–8
  22. Hippisley-Cox J, Pringle M, Hammersley V, et al. Antidepressants as risk factor for ischaemic heart disease: case-control study in primary care. BMJ. 2001;323:666–669
  23. Tata LJ, West J, Smith C, et al. General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial, infarction. Heart. 2005;91:465–471
  24. Ray WA, Meredith S, Thapa PB, Hall K, Murray KT. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther. 2004;75:234–241
  25. Raskin J, Smith TR, Wong K, et al. Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. J Palliat Med. 2006;9:29–40
  26. Wernicke J, Lledó A, Raskin J, Kajdasz DK, Wang F. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf. 2007;30:437–455
  27. McIntyre RS, Panjwani ZD, Nguyen HT, et al. The hepatic safety profile of duloxetine: a review. Expert Opin Drug Metab Toxicol. 2008;4:281–285
  28. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain. 2004;100:697–706
  29. Fava M, Mulroy R, Alpert J, Nierenberg AA, Rosenbaum JF. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry. 1997;154:1760–1762
  30. Möller HJ, Baldwin DS, Goodwin G, et al. WPA Section on Pharmacopsychiatry Do SSRIs or antidepressants in general increase suicidality? (WPA Section on Pharmacopsychiatry: consensus statement). Eur Arch Psychiatry Clin Neurosci. 2008;258(suppl 3):3–23
  31. Kalinin VV. Suicidality and antiepileptic drugs: is there a link?. Drug Saf. 2007;30:123–142
  32. Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2002;59:1015–1021
  33. Højsted J, Sjøgren P. Addiction to opioids in chronic pain patients: a literature review. Eur J Pain. 2007;11:490–518
  34. Jones D, Story DA. Serotonin syndrome and the anaesthetist. Anaesth Intensive Care. 2005;33:181–187
  35. Vranken JH, Dijkgraaf MG, Kruis MR, van der Vegt MH, Hollman MW, Heesen M. Pregabalin in patients with central neuropathic pain: a randomized, double-blind, placebo-controlled trial of a flexible-dose regimen. Pain. 2008;136:150–157
  36. O'Connor AB, Schwid SR, Markman J, Hermann D, Dworkin RH. Pain associated with multiple sclerosis: systematic review and proposed classification. Pain. 2008;137:96–111
  37. Cruccu G, Aziz TZ, Garcia-Larrea L, et al. EFNS guidelines on neurostimulation therapy for neuropathic pain. Eur J Neurol. 2007;14:952–970

 Dr. O'Connor has received support from the Mayday Fund, and the US National Institutes of Health (NIH). Dr. Dworkin has received support from the NIH and the US Veterans Administration (VA). He is a Special Government Employee of the US Food and Drug Administration Center for Drug Evaluation and Research (FDA CDER).

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9343(09)00396-9

doi: 10.1016/j.amjmed.2009.04.007

The American Journal of Medicine
Volume 122, Issue 10, Supplement , Pages S22-S32 , October 2009

Article Tools